Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

Trial Profile

A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB 4211 (Primary)
  • Indications Non-alcoholic steatohepatitis; Obesity
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
  • Sponsors CohBar
  • Most Recent Events

    • 05 Nov 2019 According to an CohBar media release, the results from both stages of the study are anticipated in mid-2020.
    • 05 Nov 2019 Results published in the CohBar Media Release.
    • 05 Nov 2019 According to an CohBar media release, the company announced the completion of the Phase 1a stage of this study and the initiation of recruitment for the Phase 1b stage.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top